Anxiety and mood (대한불안의학회지)

Korean Academy of Anxiety Disorders (대한불안의학회)
권호 표지

Associations between Clinical Characteristics and Plasma BDNF Levels of Panic Disorder

공황장애의 임상적 특성과 Brain-Derived Neurotrophic Factor 농도와의 관계

  • Hwang, In-Ho (Department of Psychiatry, Chonbuk National University Hospital) ;
  • Park, Jong-Il (Department of Psychiatry, Chonbuk National University Hospital) ;
  • Yang, Jong-Chul (Department of Psychiatry, Chonbuk National University Hospital)
  • 황인호 (전북대학교병원 정신건강의학과) ;
  • 박종일 (전북대학교병원 정신건강의학과) ;
  • 양종철 (전북대학교병원 정신건강의학과)
  • Received : 2015.08.11
  • Accepted : 2015.10.03
  • Published : 2015.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Brain-derived neurotrophic factor (BDNF) is implicated in the pathophysiology of several neuropsychiatric disorders. However, there are few studies on BDNF of panic disorder. In this study, we investigated plasma BDNF levels in patients with panic disorder, and evaluated whether there are associations between clinical characteristics of panic disorder and plasma BDNF levels. Methods : We included 110 patients with panic disorder and 110 health controls in the current study. Plasma BDNF levels were measured by the enzyme-linked immunosorbent assay (ELISA). Plasma BDNF level differences were evaluated according to the clinical characteristics, such as duration of illness, recent stressful life event, agoraphobia, and insomnia. Results : The mean plasma BDNF levels of patients with panic disorder were significantly lower, as compared with those of controls (192.50 pg/mL vs. 693.75 pg/mL, t=8.838, p<0.001). The mean plasma BDNF levels of patients who had recent stressful life events were significantly higher, as compared with those who did not ($269.79{\pm}358.96pg/mL$ vs. $136.94{\pm}187.06pg/mL$, t=-2.525, p=0.013). Conclusion : These results suggested that BDNF plays a potential role in the pathophysiology of panic disorder.

Keywords

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington: American Psychiatric Publishing;1994. p.430-443.
  2. Hirschfeld RM. Panic Disorder: Diagnosis, epidemiology, and clinical course. J Clin Psychiatry 1996;57:3-8.
  3. Sadock BJ, Sadock VA: Panic disorder and agoraphobia. In: Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Baltimore: Williams and Wilkins;2003. p. 599-609.
  4. Rosenbaum JF, Pollack MH, Pollock RA: Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry 1996;57 Suppl 10:44-48: discussion 49-50.
  5. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. AMJ Psychiatry 1994;151:413-420 https://doi.org/10.1176/ajp.151.3.413
  6. Eaton W W, Keyl PM: The epidemiology of panic. In: Panic Disorder: Clinical, Biological, and Treatment Aspects. New York: John Wiley & Sons, Inc. ; 1995.p. 50-65.
  7. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry 1982;39:701-703. https://doi.org/10.1001/archpsyc.1982.04290060051010
  8. Coryell W, Noyes R Jr, House JD. Mortality among outpatients with anxiety disorders. Am J Psychiatry 1986;143:508-510. https://doi.org/10.1176/ajp.143.4.508
  9. Rosen JB. The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev 2004;3:23-41. https://doi.org/10.1177/1534582304265945
  10. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505. https://doi.org/10.1176/appi.ajp.157.4.493
  11. Nesse RM, Cameron OG, Curtis GC, Mccann DS, Huber-Smith MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984;41:771-776. https://doi.org/10.1001/archpsyc.1984.01790190045005
  12. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacol 2006;31: 1-11. https://doi.org/10.1038/sj.npp.1301265
  13. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998; 44:812-824. https://doi.org/10.1016/S0006-3223(98)00210-8
  14. Bremner JD, Innis RB, White T, Fujita M, Silbersweig d, Goddard AW, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000;47:96-106. https://doi.org/10.1016/S0006-3223(99)00188-2
  15. Malizia AL, Cunningham VJ, Bell CJ, Liddle PE, Jones T, Nutt DJ. Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-720. https://doi.org/10.1001/archpsyc.55.8.715
  16. Abelson JL, Khan S, Liberzon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety 2007;24:66-76. https://doi.org/10.1002/da.20220
  17. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996;19:289-317. https://doi.org/10.1146/annurev.ne.19.030196.001445
  18. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors: from molecule to man. Trends Neurosci 1994;17:182-190. https://doi.org/10.1016/0166-2236(94)90099-X
  19. Numata S, Veno S, Iga J, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neutrotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006;401:1-5. https://doi.org/10.1016/j.neulet.2006.02.054
  20. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009;466:139-143. https://doi.org/10.1016/j.neulet.2009.09.044
  21. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, et al. Increased levels of plasma brain-derived neurotrophic factor (BONF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1824-1828. https://doi.org/10.1016/j.pnpbp.2008.08.005
  22. Fluimura H, Altar Ca, Chen R, Nakamura T, Nakabashi T, Kambayashi, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002;87:728-734. https://doi.org/10.1055/s-0037-1613072
  23. Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, et al. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995;6:465-471. https://doi.org/10.1006/prep.1995.1062
  24. Pan W, Banks WA, Fasold MB. Bluth J, Kastin AJ. Transport of brainderived neurotrophic factor across the blood-brain barrier. Neuropharmacol 1998;37: 1553-1561. https://doi.org/10.1016/S0028-3908(98)00141-5
  25. Poduslo JF, Curran GL. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996;36:280-286. https://doi.org/10.1016/0169-328X(95)00250-V
  26. Kobayashi K, Shimizu E. Hashimoto K. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog neuro-psychopharmacol Biol Psychiatry 2005;29:658-663. https://doi.org/10.1016/j.pnpbp.2005.04.010
  27. Lam P, Cheng CY, Hong CJ, Tsai SJ. Association study of a BrainDerived Neurotrophic Factor (Val 66Met) Genetic polymorphism and Panic disorder. Neuropsychobiol 2004;49:178-181. https://doi.org/10.1159/000077362
  28. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research;1995.
  29. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and Reliability of the Korean Version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc 2005;44:456-465.
  30. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders-Non-Patient Edition (SCIDI/NP), version 2.0. New York, New York State Psychiatric Institute, Biometrics Research;1996.
  31. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA Recommendations for the Long-Term Treatment of Panic Disorder. CNS Spectrums 2003;8:S17-S30. https://doi.org/10.1017/S109285290000691X
  32. Fiammetta C. The psychological development of panic disorder: implications for neurobiology and treatment. Rev Bras Psiquiatr 2012;34:S09-S31 https://doi.org/10.1590/S1516-44462012000500003
  33. Holmes TH, Rahe RH. The social readjustment rating scale. Journal of Psychosomatic Research 1967;11(2):213-218. https://doi.org/10.1016/0022-3999(67)90010-4
  34. Hong KE, Jeong DU. Construction of Korean 'social readjustment rating scale' -A methodological study-. Journal of Korean Neuropsychiatric Association 1982;21: 123-136.
  35. Beck AT, Steer RA, Brown G K. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation;1996.
  36. Spielberger C. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA; 1983.
  37. Kim JB. Development of the Korean Version of the Panic Disorder Severity Scale. Korean J Psychopathol 2001;10:140-151.
  38. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychology 1959;32:50-55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
  39. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996;709:122-301. https://doi.org/10.1016/0006-8993(95)01321-0
  40. Gold SM, Schulz KH, Hartmann S, Mladek M, Lang UE, Hellweg R, et al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 2003;138:99-105. https://doi.org/10.1016/S0165-5728(03)00121-8
  41. Angelucci F, Oliviero A, Pilato F, Saturno E, Dileone M, Versace V, et al. Transcranial magnetic stimulation and BDNF plasma levels in amyotrophic lateral sclerosis. Neuroreport 2004;15:717-720. https://doi.org/10.1097/00001756-200403220-00029
  42. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068-1072. https://doi.org/10.1016/j.biopsych.2005.01.008
  43. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-295. https://doi.org/10.1016/S0006-3223(96)00345-9
  44. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-1317. https://doi.org/10.1176/ajp.153.10.1313
  45. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:849-853. https://doi.org/10.1016/j.pnpbp.2009.04.002
  46. Lee BH, Kim YK. BDNF mRNA in peripheral blood mononuclear cells of depressive patients with or without attempted suicide. Poster presentation in The Korean Neuropsychiatric Association The 50th Annual Meeting;2007.
  47. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004;27:589-594. https://doi.org/10.1016/j.tins.2004.08.001
  48. Brindle PK, Montminy MR. The CREB family of transcription activators. Curr Opin Genet Dev 1992:2:199-204. https://doi.org/10.1016/S0959-437X(05)80274-6
  49. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372. https://doi.org/10.1523/JNEUROSCI.16-07-02365.1996
  50. Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997;836:158-181. https://doi.org/10.1111/j.1749-6632.1997.tb52359.x
  51. Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001;11:307-321. https://doi.org/10.1016/S0924-977X(01)00100-6
  52. Van Der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001;16:S49-S64. https://doi.org/10.1002/hup.270
  53. Baldwin DS, Waldman S, Allqulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. lnt J Neuropsychopharmacol 2011;14:697-710. https://doi.org/10.1017/S1461145710001434
  54. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992;59:99-106. https://doi.org/10.1111/j.1471-4159.1992.tb08880.x
  55. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995;15:1768-1777. https://doi.org/10.1523/JNEUROSCI.15-03-01768.1995
  56. Marmigere F, Givalois L, Rage F, Arancibia S, Tapia-Arancibia L. Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats. Hippocampus 2003;13:646-655. https://doi.org/10.1002/hipo.10109
  57. Molteni R, Calabrese F, Cattaneo A, Mancini M, Gennarelli M, Racagni G, et al. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacol 2009;34:1523-1532. https://doi.org/10.1038/npp.2008.208
  58. Lee BH, Kim YK. The Meaning of BDNF Level Measured in Blood of Depressed Patients. J Korean Neuropsyehiatr Assoc 2009;48:203-206
  59. Murakamia S, Imbea H, Morikawa Y, Kubob C, Senbaa E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neuroscience Research 2005;53: 129-139. https://doi.org/10.1016/j.neures.2005.06.008
  60. Ziegenhorn AA, Schulte-Herbruggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, et al. Serum neurotrophins: a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007;28:1436-1445. https://doi.org/10.1016/j.neurobiolaging.2006.06.011
  61. Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S, Knudsen GM. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 2007;73:143 https://doi.org/10.1016/j.brainresbull.2007.03.009
  62. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005;26:115-123. https://doi.org/10.1016/j.neurobiolaging.2004.03.002